Mounjaro vs Wegovy: Which GLP-1 Actually Wins on Weight Loss in 2026?

Tirzepatide (Mounjaro/Zepbound) produces meaningfully greater weight loss than semaglutide (Wegovy) — and the SURMOUNT-5 trial settled the debate with direct head-to-head data. At 72 weeks, tirzepatide users lost 20.2% of body weight versus 13.7% for semaglutide, with nearly twice as many tirzepatide patients hitting the 25% weight-loss threshold [2][4].

What the Head-to-Head Trial Actually Found

SURMOUNT-5, published in the New England Journal of Medicine in May 2025, enrolled 751 adults with obesity or overweight — no type 2 diabetes — and randomized them to maximum tolerated doses of either tirzepatide (10 or 15 mg weekly) or semaglutide (1.7 or 2.4 mg weekly, the Wegovy dosing schedule) [2]. The result wasn't close: tirzepatide delivered roughly 47% more relative weight loss. About 31.6% of tirzepatide patients hit ≥25% body-weight reduction versus 16.1% on semaglutide [4].

Critically, tolerability was nearly identical between arms. Nausea affected roughly 44% of participants in each group, and gastrointestinal adverse events were mild-to-moderate in both cases — dual GIP/GLP-1 agonism doesn't appear to carry a meaningfully worse side-effect burden than GLP-1-only therapy [2]. Both drugs also carry the same FDA black-box warning for theoretical thyroid C-cell tumor risk based on rodent data, and both are contraindicated in patients with MEN2 or medullary thyroid carcinoma history.

For context on semaglutide's standalone performance, the STEP-1 trial (published in NEJM) showed Wegovy users averaging 14.9% weight loss over 68 weeks — impressive by historical standards, but now clearly the second-best result when tirzepatide is in the room. If you want the deeper semaglutide-specific breakdown, see our tirzepatide vs semaglutide comparison for 2026.

Where Wegovy Still Has an Edge

Weight loss magnitude isn't the only variable that matters clinically. Wegovy holds a cardiovascular risk-reduction indication — backed by the SELECT trial (NEJM, 2023), which showed semaglutide reduced major adverse cardiovascular events by 20% in patients with established CVD and obesity [2]. Tirzepatide does not yet have an equivalent cardiovascular outcomes label, though trials are ongoing.

Wegovy also has a longer post-marketing safety record, more insurance coverage pathways, and broader real-world prescriber familiarity. For patients with established heart disease, a clinician may reasonably choose Wegovy regardless of the weight-loss gap. For a current look at how cardiovascular data are shaping prescribing, the semaglutide cardiovascular outcomes evidence is worth reviewing.

Real-world data from a propensity-matched JAMA Internal Medicine cohort of 18,386 adults mirrors the trial findings: tirzepatide users were 2.54× more likely to achieve ≥10% weight loss and 3.24× more likely to hit ≥15% within one year compared with semaglutide users [7]. The advantage held at 3, 6, and 12 months — this isn't a late-appearing effect, it's consistent across the treatment arc.

If you're evaluating your options, Marek Health's weight management program offers access to both tirzepatide and semaglutide protocols with clinical oversight, which matters given that dose titration is where most patients struggle.

The Bottom Line on Choosing Between Them

For pure weight-loss efficacy, tirzepatide wins — the SURMOUNT-1 and SURMOUNT-5 data are unambiguous [5][6]. The dual GIP/GLP-1 mechanism produces larger fat-mass reductions (roughly 34% of fat mass lost in SURMOUNT-1 sub-studies) without disproportionate lean-mass loss, and a higher fraction of patients reach the ≥20% and ≥25% thresholds that correlate with meaningful metabolic improvement [6].

That said, the "right" drug depends on your clinical picture. Cardiovascular disease history, insurance formulary, prior GI sensitivity, and access to compounded versions (generic semaglutide and generic tirzepatide are both available through 503A/503B compounding pharmacies at lower cost) all factor in. Explore the full landscape of medically supervised options at the weight management treatment hub or compare telehealth providers at Alpha Health Finder's weight-loss directory.

---

Frequently asked questions

Which drug causes more weight loss — Mounjaro or Wegovy?

Tirzepatide (Mounjaro/Zepbound) produces greater weight loss than semaglutide (Wegovy) based on direct head-to-head evidence from SURMOUNT-5. Participants on tirzepatide lost an average of 20.2% of body weight at 72 weeks versus 13.7% on semaglutide, and tirzepatide users were roughly twice as likely to achieve ≥25% weight reduction [2][4]. The difference is attributed to tirzepatide's dual GIP/GLP-1 mechanism versus semaglutide's GLP-1-only action.

Are the side effects worse with tirzepatide than with Wegovy?

No — side-effect profiles are broadly similar between the two drugs. In SURMOUNT-5, nausea rates were approximately equal (~44% in both arms), and gastrointestinal events were predominantly mild to moderate in both groups [2]. Both drugs carry identical FDA black-box warnings about theoretical thyroid C-cell tumor risk based on animal studies, and both are contraindicated in patients with MEN2